Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue

Journal of Neurochemistry

Volumn 93, Issue 2, 2005, Pages 299-309

  Petersen, Gitte ^a   Moesgaard, Birthe ^a   Schmid, Patricia C ^b   Schmid, Harald H O ^b   Broholm, Helle ^c   Kosteljanetz, Michael ^c   Hansen, Harald S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF MINNESOTA   (United States)

^c University of Copenhagen   (Denmark)

Author keywords

2 arachidonoyl glycerol; Anandamide; Fatty acid amide hydrolase; N acylethanolamine; N acylphosphatidylethanolamine hydrolysing phospholipase D

Indexed keywords

ACYLTRANSFERASE; ANANDAMIDE; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; FATTY ACID AMIDASE; MONOACYLGLYCEROL; N ACYLTRANSFERASE; N-ACYLETHANOLAMINES; N-ACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE D; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TISSUE; CANCER GRADING; ENZYME ACTIVITY; GAS CHROMATOGRAPHY; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MENINGIOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; WORLD HEALTH ORGANIZATION;

BRAIN; BRAIN NEOPLASMS; ENDOCANNABINOIDS; GLIOBLASTOMA; HUMANS; MENINGIOMA;

EID: 17444373124     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03013.x     Document Type: Article

References (69)

1. Bartlett G. R. (1959) Phosphorous assay in column chromatography. J. Biol. Chem. 234, 466-468.
2. Bifulco M. and Di Marzo V. (2002) Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat. Med. 8, 547-550.
3. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L. and Di Marzo V. (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745-2747.
4. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G. and Di Marzo V. (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18, 1606-1608.
5. Blázquez C., Casanova M. L., Planas A., Gómez del Pulgar T., Villanueva C., Fernandez-Acenero M. J., Aragones J., Huffman J. W., Jorcano J. L. and Guzmán M. (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17, 529-531.
6. Blázquez C., Gonzalez-Feria L., Alvarez L., Haro A., Casanova M. L. and Guzmán M. (2004) Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64, 5617-5623.
7. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
8. Casanova M. L., Blázquez C., Martinez-Palacio J., Villanueva C., Fernández-Acenero M. J., Huffman J. W., Jorcano J. L. and Guzmán M. (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50.
9. Contassot E., Tenan M., Schnuriger V., Pelte M. F. and Dietrich P. Y. (2004) Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol. 93, 182-188.
10. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M. and Di Marzo V. (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl Acad. Sci. USA 95, 8375-8380.
11. De Petrocellis L., Bisogno T., Ligresti A., Bifulco M., Melck D. and Di Marzo V. (2002) Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam. Clin. Pharmacol. 16, 297-302.
12. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A. and Mechoulam R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
13. Di Marzo V., De Petrocellis L., Sugiura T. and Waku K. (1996) Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227, 281-288.
14. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z. and De Petrocellis L. (2001) Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358, 249-255.
15. Folch J., Lees M. and Stanley G. H. S. (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509.
16. Foster D. A. and Xu L. (2003) Phospholipase D in cell proliferation and cancer. Mol. Cancer Res. 1, 789-800.
17. Fowler C. J., Jonsson K. O., Andersson A., Juntunen J., Jarvinen T., Vandevoorde S., Lambert D. M., Jerman J. C. and Smart D. (2003) Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem. Pharmacol. 66, 757-767.
18. Fu J., Gaetani S., Oveisi F. et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425, 90-93.
19. Galve-Roperh I., Sánchez C., Cortes M. L., Gómez del Pulgar T., Izquierdo M. and Guzmán M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313-319.
20. Gaoni Y. and Mechoulam R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647.
21. Gómez del Pulgar T., Velasco G., Sánchez C., Haro A. and Guzmán M. (2002) De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem. J. 363, 183-188.
22. Gunther W., Skaftnesmo K. O., Arnold H. and Terzis A. J. (2003) Molecular approaches to brain tumour invasion. Acta Neurochir. (Wien) 145, 1029-1036.
23. Guzmán M., Sánchez C. and Galve-Roperh I. (2001) Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613-625.
24. Guzmán M., Sánchez C. and Galve-Roperh I. (2002) Cannabinoids and cell fate. Pharmacol. Ther. 95, 175-184.
25. Hansen H. H., Schmid P. C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H. H. O., Fernandez-Ruiz J. J. and Hansen H. S. (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415-1427.
26. Hansen H. S., Moesgaard B., Hansen H. H. and Petersen G. (2000) N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipids 108, 135-150.
27. Hart S., Fischer O. M. and Ullrich A. (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64, 1943-1950.
28. Jacobsson S. O. P., Wallin T. and Fowler C. J. (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299, 951-959.
29. Jessani N., Liu Y., Humphrey M. and Cravatt B. F. (2002) Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl Acad. Sci. USA 99, 10 335-10 340.
30. Jessani N., Humphrey M., McDonald W. H., Niessen S., Masuda K., Gangadharan B., Yates J. R.., III, Mueller B. M. and Cravatt B. F. (2004) Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc. Natl Acad. Sci. USA 101, 13756-13761.
31. Jones S. and Howl J. (2003) Cannabinoid receptor systems: therapeutic targets for tumour intervention. Expert Opin. Ther. Targets 1, 749-758.
32. Kirazov L. P., Venkov L. G. and Kirazov E. P. (1993) Comparison of the Lowry and the Bradford protein assays as applied for protein estimation of membrane-containing fractions. Anal. Biochem. 208, 44-48.
33. Kishikawa K., Chalfant C. E., Perry D. K., Bielawska A. and Hannun Y. A. (1999) Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses. J. Biol. Chem. 274, 21 335-21 341.
34. Kleihues P. and Cavenee W. K. (2000) World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon.
35. Kokoglu E.,Tuter Y., Yazici Z., Sandikci K. S., Sonmez H., Ulakoglu E. Z. and Ozyurt E. (1998) Profiles of the fatty acids in the plasma membrane of human brain tumors. Cancer Biochem. Biophys. 16, 301-312.
36. Ligresti A., Bisogno T., Matias I. et al. (2003) Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687.
37. Liu Y., Patricelli M. P. and Cravatt B. F. (1999) Activity-based protein profiling: the serine hydrolases. Proc. Natl Acad. Sci. USA 96, 14 694-14 699.
38. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A. and Piomelli D. (2005) The nuclear receptor PPAR-α mediates the antiinflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19.
39. Maccarrone M., Lorenzon T., Bari M., Melino G. and Finazzi-Agrò A. (2000) Anandarmide induces apoptosis in human cells via vanilloid receptors - Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31 938-31 945.
40. Maccarrone M., Attinà M., Cartoni A., Bari M. and Finazzi-Agro A. (2001) Gas chromatography-mass spectrometry analysis of endogenous cannabinoid in healthy and tumoral human brain and human cells in culture. J. Neurochem. 76, 594-601.
41. Maccarrone M., Pauselli R., Di Rienzo M. and Finazzi-Agro A. (2002) Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem. J. 366, 137-144.
42. Martin D. D., Robbins M. E. C., Spector A. A., Wen B. C. and Hussey D. H. (1996) The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids 31, 1283-1288.
43. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
44. McKallip R. J., Lombard C., Fisher M., Martin B. R., Ryu S., Grant S., Nagarkatti P. S. and Nagarkatti M. (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634.
45. Mechoulam R., Ben-Shabat S., Hanus L. et al. (1995) Identification of en endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
46. Melck D., De Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M. and Di Marzo V. (2000) Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126.
47. Mimeault M., Pommery N., Wattez N., Bailly C. and Henichart J. P. (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56, 1-12.
48. 31P NMR and enzyme activity study. J. Lipid Res. 41, 985-990.
49. Moesgaard B., Petersen G., Mortensen S. A. and Hansen H. S. (2002) Substantial species differences in relation to formation and degradation of N-acyl-ethanolamine phospholipids in heart tissue: an enzyme activity study. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 131, 475-482.
50. Moesgaard B., Hansen H. H., Hansen S. L., Hansen S. H., Petersen G. and Hansen H. S. (2003) Brain levels of N-acylethanolamine phospholipids in mice during pentylenetetrazol-induced seizure. Lipids 38, 387-390.
51. Munro S., Thomas K. L. and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
52. Newton H. B. (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. 4, 105-128.
53. 14C] as a substrate for anandamide amidase. Life Sci. 56, 1999-2005.
54. Pagotto U., Marsicano G., Fezza F. et al. (2001) Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 86, 2687-2696.
55. Petersen G., Chapman K. D. and Hansen H. S. (2000) A rapid phospholipase D assay using zirconium precipitation of anionic substrate phospholipids: application to N-acylethanolamine formation in vitro, J. Lipid Res. 41, 1532-1538.
56. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V. and Bifulco M. (2003) Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771-1773.
57. Porter A. C. and Felder C. C. (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther. 90, 45-60.
58. Riboni L., Ghidoni R., Sonnino S., Omodeo-Sale F., Gaini S. M. and Berra B. (1984) Phospholipid content and composition of human meningiomas. Neurochem. Pathol. 2, 171-188.
59. Riboni L., Campanella R., Bassi R., Villani R., Gaini S. M., Martinelli-Boneschi F., Viani P. and Tettamanti G. (2002) Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39, 105-113.
60. 9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436, 6-10.
61. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54, 834-843.
62. 2 cannabinoid receptor. Cancer Res. 61, 5784-5789.
63. Schmid H. H. O. (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids 108, 71-87.
64. Schmid P. C., Schwartz K. D., Smith C. N., Krebsbach R. J., Berdyshev E. V. and Schmid H. H. O. (2000) A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanolamines and 2-monoacylglycerols. Chem. Phys. Lipids 104, 185-191.
65. Schmid P. C., Wold L. E., Krebsbach R. J., Berdyshev E. V. and Schmid H. H. O. (2002) Anandamide and other N-acylethanolamines in human tumors. Lipids 37, 907-912.
66. Stella N., Schweitzer P. and Piomelli D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
67. Sugita M., Williams M., Dulaney J. and Moser H. (1975) Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim. Biophys. Acta 398, 125-133.
68. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A. and Waku K. (1995) 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97.
69. Vinggaard A. M., Jensen T., Morgan C. P., Cockcroft S. and Hansen H. S. (1996) Didecanoyl phosphatidylcholine is a superior substrate for assaying mammalian phospholipase D. Biochem. J. 319, 861-864.